OS	overall survival
PD-1	programmed cell death protein-1
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
LAG-3	lymphocyte activation gene-3
TIGIT	T-cell immunoglobulin and ITIM domain
TIM-3	T-cell immunoglobulin- and mucin-domain-containing molecule-3
VISTA	V-domain Immunoglobulin Suppressor of T-cell Activation
IDO1	indoleamine 2, 3-dioxygenase 1
IDO2	indoleamine 2, 3-dioxygenase 2
TDO	tryptophan 2, 3-dioxygenase
B7-H3	B7 homolog 3 protein
HVEM	herpesvirus entry mediator
BTLA	B- and T-lymphocyte attenuator
MHC	major histocompatibility complex
TCR	T-cell receptor
TME	tumor microenvironment
HLA	human leukocyte antigen
DCR	disease control rate
PFS	progress-free survival
TIL	tumor-infiltrating leukocytes
IFN-γ	interferon gamma
TMB	tumor mutational burden
mAb	monoclonal antibody
TRAE	treatment-related adverse event
RFS	relapse-free survival
ORR	objective response rate
mDOR	median duration of response
DLT	dose-limiting toxicity
NK cells	natural killer cells
CAECAM1	carcinoembryonic antigen-related cell adhesion molecule 1
HMGB1	high-mobility-group box 1
ITIM	immunoreceptor tyrosine-based inhibitory motif
ADCC	antibody-dependent cellular cytotoxicity
MDSC	myeloid-derived suppressor cells
CR	complete response
APC	antigen-presenting cells
CTL	cytotoxic lymphocyte
DC	dendritic cell
GPI	glycosylphosphatidylinositol
miRNA	microRNA